Zoetis (ZTS) Cash & Equivalents (2012 - 2026)

Zoetis (ZTS) has 15 years of Cash & Equivalents data on file, last reported at $1.9 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.9 billion, up 12.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 12.78% YoY), and the FY2025 annual result was $2.4 billion, up 23.3% from the prior year.
• Cash & Equivalents retreated to $1.9 billion in Q1 2026 per ZTS's latest filing, from $2.4 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $3.6 billion in Q4 2022 and troughed at $1.4 billion in Q2 2025.
• A 5-year average of $2.1 billion and a median of $2.0 billion in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents sank 43.0% in 2023, then increased 23.3% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $3.6 billion in 2022, then slumped by 43.0% to $2.0 billion in 2023, then fell by 2.65% to $2.0 billion in 2024, then advanced by 23.3% to $2.4 billion in 2025, then slipped by 20.78% to $1.9 billion in 2026.
• Business Quant data shows ZTS's Cash & Equivalents at $1.9 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.1 billion in Q3 2025.